Effects of treatment with SGLT2 inhibitor on the initiation of continuous positive airway pressure therapy in type 2 diabetic patients with obstructive sleep apnea syndrome

Effects of treatment with SGLT2 inhibitor on the initiation of continuous positive airway pressure therapy in type 2 diabetic patients with obstructive sleep apnea syndrome - Effects of treatment with SGLT2 inhibitor on the initiation of C-PAP therapy in type 2 diabetic patients with OSAS

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000045226

Enrollment

Registered

2021-08-23

Start date

2020-04-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 2 diabetes

Interventions

The type 2 diabetic patients having obstructive sleep apnea syndrome are treated with 2.5 mg/day luseogliflozin, 5 mg/day dapagliflozin, or 10 mg/day empagliflozin for more than 6 months. And then the

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Hemoglobin A1c level: 6.5-9.5%

Exclusion criteria

Exclusion criteria: eGFR<45 mL/min/1.73 m2

Design outcomes

Primary

Measure	Time frame
HbA1c, BMI, and apnea-hypopnea index	—

Secondary

Measure	Time frame
Serum lipid profile, serum parameters of hepatic function, and serum uric acid level	—

Countries

Japan

Contacts

Public ContactMasataka Kusunoki

Nagoya University Research Center of Health, Physical Fitness and Sports

kusunoki@tonyo.jp052-789-3946

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026